Does the media refer more to COYA or RCKT?

In the previous week, Coya Therapeutics had 9 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 14 mentions for Coya Therapeutics and 5 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.35 beat Coya Therapeutics' score of 0.53 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BNTC or COYA?

In the previous week, Coya Therapeutics had 12 more articles in the media than Benitec Biopharma. MarketBeat recorded 14 mentions for Coya Therapeutics and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.71 beat Coya Therapeutics' score of 0.53 indicating that Benitec Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Benitec Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Coya Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate COYA or PRTC?

Coya Therapeutics currently has a consensus target price of $15.33, indicating a potential upside of 237.74%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Coya Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, COYA or PRTC?

Coya Therapeutics has higher revenue and earnings than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coya Therapeutics $7.95M 13.40 -$21.23M -$1.07 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Does the media prefer ARCT or COYA?

In the previous week, Coya Therapeutics had 11 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 14 mentions for Coya Therapeutics and 3 mentions for Arcturus Therapeutics. Coya Therapeutics' average media sentiment score of 0.53 beat Arcturus Therapeutics' score of 0.39 indicating that Coya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Coya Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COYA or LRMR?

In the previous week, Coya Therapeutics had 10 more articles in the media than Larimar Therapeutics. MarketBeat recorded 14 mentions for Coya Therapeutics and 4 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.19 beat Coya Therapeutics' score of 0.53 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Larimar Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Coya Therapeutics (COYA) Competitors

$4.53 -0.03 (-0.66%)

As of 03:43 PM Eastern

Compare

COYA vs. RCKT, BNTC, PRTC, ARCT, and LRMR

Should you buy Coya Therapeutics stock or one of its competitors? Coya Therapeutics's main competitors and comparable companies include Rocket Pharmaceuticals (RCKT), Benitec Biopharma (BNTC), PureTech Health (PRTC), Arcturus Therapeutics (ARCT), and Larimar Therapeutics (LRMR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Coya Therapeutics compare to Rocket Pharmaceuticals?

Coya Therapeutics (NASDAQ:COYA) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Coya Therapeutics' return on equity of -52.05% beat Rocket Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Coya Therapeutics currently has a consensus price target of $15.33, suggesting a potential upside of 237.74%. Rocket Pharmaceuticals has a consensus price target of $8.57, suggesting a potential upside of 129.18%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Coya Therapeutics is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

In the previous week, Coya Therapeutics had 9 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 14 mentions for Coya Therapeutics and 5 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.35 beat Coya Therapeutics' score of 0.53 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coya Therapeutics has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Coya Therapeutics has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	13.40	-$21.23M	-$1.07	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

Summary

Coya Therapeutics beats Rocket Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to Benitec Biopharma?

Benitec Biopharma (NASDAQ:BNTC) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 4.8% of Benitec Biopharma shares are held by insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Benitec Biopharma has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Coya Therapeutics has higher revenue and earnings than Benitec Biopharma. Benitec Biopharma is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benitec Biopharma	N/A	N/A	-$37.92M	-$1.14	N/A
Coya Therapeutics	$7.95M	13.40	-$21.23M	-$1.07	N/A

Benitec Biopharma has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Benitec Biopharma's return on equity of -34.82% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benitec Biopharma	N/A	-34.82%	-34.11%
Coya Therapeutics	-270.22%	-52.05%	-46.34%

In the previous week, Coya Therapeutics had 12 more articles in the media than Benitec Biopharma. MarketBeat recorded 14 mentions for Coya Therapeutics and 2 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.71 beat Coya Therapeutics' score of 0.53 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Benitec Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Coya Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Benitec Biopharma presently has a consensus price target of $24.80, indicating a potential upside of 100.16%. Coya Therapeutics has a consensus price target of $15.33, indicating a potential upside of 237.74%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Benitec Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benitec Biopharma	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Coya Therapeutics beats Benitec Biopharma on 9 of the 15 factors compared between the two stocks.

How does Coya Therapeutics compare to PureTech Health?

Coya Therapeutics (NASDAQ:COYA) and PureTech Health (NASDAQ:PRTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

Coya Therapeutics has higher revenue and earnings than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	13.40	-$21.23M	-$1.07	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Coya Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

PureTech Health has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. PureTech Health's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
PureTech Health	N/A	N/A	N/A

In the previous week, Coya Therapeutics had 14 more articles in the media than PureTech Health. MarketBeat recorded 14 mentions for Coya Therapeutics and 0 mentions for PureTech Health. Coya Therapeutics' average media sentiment score of 0.53 beat PureTech Health's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coya Therapeutics	Positive
PureTech Health	Neutral

Coya Therapeutics currently has a consensus target price of $15.33, indicating a potential upside of 237.74%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Coya Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 5.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Coya Therapeutics beats PureTech Health on 9 of the 14 factors compared between the two stocks.

How does Coya Therapeutics compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Coya Therapeutics has a net margin of -270.22% compared to Arcturus Therapeutics' net margin of -317.62%. Arcturus Therapeutics' return on equity of -46.54% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-317.62%	-46.54%	-36.46%
Coya Therapeutics	-270.22%	-52.05%	-46.34%

Arcturus Therapeutics has a beta of 2.39, meaning that its share price is 139% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

In the previous week, Coya Therapeutics had 11 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 14 mentions for Coya Therapeutics and 3 mentions for Arcturus Therapeutics. Coya Therapeutics' average media sentiment score of 0.53 beat Arcturus Therapeutics' score of 0.39 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Coya Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcturus Therapeutics presently has a consensus target price of $20.00, suggesting a potential upside of 21.21%. Coya Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 237.74%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Arcturus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.60
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Coya Therapeutics has lower revenue, but higher earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	5.72	-$65.78M	-$3.31	N/A
Coya Therapeutics	$7.95M	13.40	-$21.23M	-$1.07	N/A

Summary

Coya Therapeutics beats Arcturus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Coya Therapeutics compare to Larimar Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Larimar Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Coya Therapeutics' return on equity of -52.05% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Larimar Therapeutics	N/A	-137.39%	-97.65%

In the previous week, Coya Therapeutics had 10 more articles in the media than Larimar Therapeutics. MarketBeat recorded 14 mentions for Coya Therapeutics and 4 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.19 beat Coya Therapeutics' score of 0.53 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Larimar Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coya Therapeutics presently has a consensus target price of $15.33, suggesting a potential upside of 237.74%. Larimar Therapeutics has a consensus target price of $11.67, suggesting a potential upside of 197.62%. Given Coya Therapeutics' higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than Larimar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Coya Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

Coya Therapeutics has higher revenue and earnings than Larimar Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	13.40	-$21.23M	-$1.07	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$1.95	N/A

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by insiders. Comparatively, 4.0% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Coya Therapeutics beats Larimar Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Coya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COYA vs. The Competition

Export

Metric	Coya Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$106.51M	$3.96B	$7.13B	$12.67B
Dividend Yield	N/A	3.61%	2.54%	10.96%
P/E Ratio	-4.24	11.84	272.59	25.06
Price / Sales	13.40	1,323.96	618.94	97.82
Price / Cash	N/A	44.06	28.78	36.03
Price / Book	2.20	16.87	11.06	6.25
Net Income	-$21.23M	-$22.72M	$3.47B	$348.99M
7 Day Performance	-9.92%	-2.58%	-0.83%	-2.35%
1 Month Performance	8.35%	11.33%	7.15%	3.03%
1 Year Performance	-30.79%	54.30%	24.62%	13.62%

Coya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COYA Coya Therapeutics	2.5875 of 5 stars	$4.53 -0.7%	$15.33 +238.5%	-30.5%	$106.27M	$7.95M	N/A	6
RCKT Rocket Pharmaceuticals	3.4233 of 5 stars	$3.91 +8.0%	$8.57 +119.2%	+13.4%	$429.24M	N/A	N/A	240	Analyst Forecast
BNTC Benitec Biopharma	2.3066 of 5 stars	$12.48 -1.5%	$24.80 +98.7%	-8.1%	$428.69M	N/A	N/A	20	Positive News
PRTC PureTech Health	0.0157 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100
ARCT Arcturus Therapeutics	2.0169 of 5 stars	$14.83 -8.3%	$20.00 +34.9%	-13.2%	$421.51M	$18.72M	N/A	180	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COYA) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coya Therapeutics (COYA) Competitors

COYA vs. RCKT, BNTC, PRTC, ARCT, and LRMR

How does Coya Therapeutics compare to Rocket Pharmaceuticals?

Summary

How does Coya Therapeutics compare to Benitec Biopharma?

Summary

How does Coya Therapeutics compare to PureTech Health?

Summary

How does Coya Therapeutics compare to Arcturus Therapeutics?

Summary

How does Coya Therapeutics compare to Larimar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coya Therapeutics (COYA) Competitors

COYA vs. RCKT, BNTC, PRTC, ARCT, and LRMR

How does Coya Therapeutics compare to Rocket Pharmaceuticals?

Is COYA or RCKT more profitable?

Do insiders and institutionals hold more shares of COYA or RCKT?

Do analysts prefer COYA or RCKT?

Does the media refer more to COYA or RCKT?

Which has more volatility and risk, COYA or RCKT?

Which has preferable valuation and earnings, COYA or RCKT?

Summary

How does Coya Therapeutics compare to Benitec Biopharma?

Do insiders & institutionals believe in BNTC or COYA?

Which has more risk and volatility, BNTC or COYA?

Which has preferable earnings and valuation, BNTC or COYA?

Is BNTC or COYA more profitable?

Does the media favor BNTC or COYA?

Do analysts rate BNTC or COYA?

Summary

How does Coya Therapeutics compare to PureTech Health?

Which has higher valuation & earnings, COYA or PRTC?

Which has more risk and volatility, COYA or PRTC?

Is COYA or PRTC more profitable?

Does the media refer more to COYA or PRTC?

Do analysts rate COYA or PRTC?

Do institutionals and insiders believe in COYA or PRTC?

Summary

How does Coya Therapeutics compare to Arcturus Therapeutics?

Do institutionals and insiders hold more shares of ARCT or COYA?

Is ARCT or COYA more profitable?

Which has more volatility and risk, ARCT or COYA?

Does the media prefer ARCT or COYA?

Do analysts prefer ARCT or COYA?

Which has higher earnings & valuation, ARCT or COYA?

Summary

How does Coya Therapeutics compare to Larimar Therapeutics?

Is COYA or LRMR more profitable?

Does the media refer more to COYA or LRMR?

Do analysts prefer COYA or LRMR?

Which has more volatility & risk, COYA or LRMR?

Which has higher valuation & earnings, COYA or LRMR?

Do institutionals & insiders have more ownership in COYA or LRMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools